Brand Name : Tecoflip
Generic Name : Teicoplanin Injection IP
Pack Size : Vial
Dosage Form : Lyophilized powder for Injection
Strength : 200 mg & 400 mg
Therapeutic indications : Teicoplanin is indicated in adults and in children from birth for the parenteral treatment of the following infections:
• complicated skin and soft tissue infections,
• bone and joint infections,
• hospital acquired pneumonia,
• community acquired pneumonia,
• complicated urinary tract infections,
• infective endocarditis,
• peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD),
• bacteraemia that occurs in association with any of the indications listed above.
Teicoplanin is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis.
Where appropriate, teicoplanin should be administered in combination with other antibacterial agents.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Pharmacotherapeutic group : Glycopeptide Antibacterials
ATC code : J01XA02
Pharmacodynamic properties : Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.
February 18, 2022
